PepGen Inc. Sued for Making False Claims About PGN-EDO51

Summary

A class-action lawsuit has been filed against PepGen Inc. (PEPG), alleging securities fraud between March 7, 2024, and March 3, 2025. The lawsuit claims the company made false statements about the efficacy and safety of its main product candidate PGN-EDO51 and that there were defects in FDA approval studies. Investors who suffered losses during this period are encouraged to contact Levi & Korsinsky LLP by August 8, 2025, for potential compensation options Acceswire.

Impact Analysis

The lawsuit against PepGen Inc. directly impacts the company by potentially damaging its reputation, leading to financial liabilities, and causing investor distrust. This may result in a decline in stock price and increased scrutiny from regulators. First-order effects include diminished growth prospects due to the questionable viability of PGN-EDO51, which was likely key to their pipeline. There is also the risk of further legal expenses and settlements. Second-order effects might include decreased investor confidence in biotech companies with similar regulatory challenges. Investment opportunities may involve options strategies such as buying puts to hedge against further stock price declines or looking for undervalued competitors in the biotech sector that are not facing similar legal issues Acceswire+ 3.